Summary
Pro-inflammatory and vasoactive mediators released from human basophils and mast cells play a role in several inflammatory and immune disorders. It was recently demonstrated that cyclosporin A (CsA) exerts anti-inflammatory effects by inhibiting the release of preformed and de novo synthesized mediators from human basophils [1]. This study compared the effects of pharmacological concentrations of deflazacort (DFZ) and prednisolone (PRED) on the anti-IgE-mediated release of preformed (histamine) and de novo synthesized (leukotriene C4: [LTC4]) mediators from basophils. Basophils were cultured for 18 hours in the presence of pharmacological concentrations of DFZ (10−8 to 3 × 10−6 M). DFZ inhibited the anti-IgE-mediated release of histamine and LTC4 from basophils in a concentration-dependent manner (6–40 %), and had a similar efficacy and potency to PRED. The effect of DFZ (10−8 to 10−8 M) in combination with CsA on the immunological release of histamine and LTC4 from basophils was also evaluated. An 18-hour incubation of basophils with DFZ (10−8 M) followed by a short (15-minute) incubation with CsA (30 ng/ml) resulted in an additive inhibition of the release of histamine and LTC4. The additive anti-inflammatory effect of these drugs makes them interesting candidates for future controlled clinical trials in inflammatory diseases in which basophil-derived mediators play a relevant role.
Similar content being viewed by others
References
Cirillo R, Triggiani MSiri LCiccarelli APettit GR, Condorelli M, Marone G (1990) Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. J Immunol 144: 3891–3897
Siegel SC (1985) Overview of corticosteroid therapy. J Allergy Clin Immunol 76: 312–320
Schleimer RP (1990) Effects of glucocorticoids on inflammatory cells relevant to their therapeutic applications in asthma. Am Rev Respir Dis 141: S59–69
Schleimer RP (1988) Glucocorticosteroids. Their mechanism of action and use in allergic diseases. In: Middleton E Jr, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW (eds) Allergy. Principles and practice. l. Mosby, St. Louis, pp 739–765
Gray RES, Doherty SM, Galloway J, Coulton L, de Broe M, Kanis JA (1991) A double-blind study of deflazacort and prednisolone in patients with chronic inflammatory disorders. Arth Rheum 34: 287–295
Kahan BD (1989) Cyclosporine. N Engl J Med 321: 1725–1738
Nussenblatt RB, Rook AH, Wacker WB, Palestine AG, Scher I, Gery I (1983) Treatment of intraocular inflammatory diseases with cyclosporin A. Lancet II: 235–238
Weinblatt ME, Coblyn JS, Fraser PA, Anderson RJ, Spragg J, Trentham DE, Austen KF (1987) Cyclosporin A treatment of refractory rheumatoid arthritis. Arth Rheum 30: 11–17
Bougneres PF, Carel JC, Boitard C et al. (1988) Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 318: 663–670
Brynskow J, Freund L, Rasmussen, et al. (1989) A placebocontrolled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 321: 845–850
Alexander AG, Barnes NC, Kay AB (1992) Cyclosporin A (CyA) in corticosteroid-dependent chronic severe asthma. A randomised double-blind placebo-controlled crossover trial. Lancet 339: 324–328
Munro CS, Higgins EM, Marks JM, Daly BM, Friedmann PS, Shuster S (1991) Cyclosporin A in atopic dermatitis: therapeutic response is dissociated from effects on allergic reactions. Br J Dermatol 124: 43–48
Secchi AG, Tognon MS, Leonardi A (1990) Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol 110: 641–645
Marone G, de Paulis A, Ciecarelli A, Casolaro V, Cirillo R (1991) Mechanism(s) of action of cyclosporin A. Seminars Clin Immunol 2: 11–16
Marone G (1992) Immunosuppressive treatment of chronic asthma. In: Lichtenstein LM, Fauci AS (eds) Current therapy in allergy, immunology, and rheumatology. 4. Mosby, Philadelphia, pp 368–371
Casolaro V, Galeone D, Giacummo A, Sanduzzi A, Melillo G, Marone G (1989) Human basophil/mast cell releasability. V Functional comparisons of cells obtained from peripheral blood, lung parenchyma and from bronchoalveolar lavage in asthmatics. Am Rev Respir Dis 139: 1375–1382
Marone G, Giugliano R, Lembo G, Ayala F (1986) Human basophil releasability. II. Changes in basophil releasability in patients with atopic dermatitis. J Invest Dermatol 87: 19–23
Dvorak AM, Monahan RA, Osage JE, Dickersin GR (1980) Crohn's disease transmission electron microscopic studies. II. Immunologic inflammatory response. Alterations of mast cells, basophils, eosinophils, and the microvasculature. Human Pathol 11: 606–619
de Paulis A, Valentini G, Spadaro G, Lupoli S, Tirri G, Marone G (1991) Human basophil releasability. VIII. Increased basophil releasability in patients with scleroderma. Arth Rheum 34: 1289–1296
Colvin RB, Dvorak HE (1974) Basophils and mast cells in renal allograft rejection. Lancet I: 212–214
Schleimer RP, Lichtenstein LM, Gillespie E (1981) Inhibition of basophil histamine release by anti-inflammatory steroids. Nature 292: 454–455
Schleimer RP, Davidson DA, Peters SP, Lichtenstein LM (1985) Inhibition of basophil leukotriene release by anti-inflammatory steroids. Int Arch Allergy Appl Immunol 77: 241–243
Krbnke M, Leonard WJ, Depper JM, Arya SK, Wong-Staal F, Gallo RC, Waldmann TA, Greene WC (1984) Cyclosporin A inhibits T -cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci USA 81: 5214–5218
Marone G, Cirillo R, Ciccarelli A, de Paulis A, Condorelli M (1990) Mechanism of action of cyclosporin A in human inflammatory cells. In: Bonomo L (ed) Cyclosporin in autoimmune diseases. Il Pensiero Scientifico, Rome, pp 1–10
Casolaro V, Spadaro G, Patella V, Marone G (1993) In vivo characterization of the anti-inflammatory effect of cyclosporin A. J Clin Invest (submitted for publication)
Casolaro V, Spadaro G, Marone G (1990) Human basophil releasability. VI. Changes in basophil releasability in patients with allergic rhinitis or bronchial asthma. Am Rev Respir Dis 142: 1108–1111
Marone G, Columbo M, Triggiani M, Cirillo R, Genovese A, Formisano S (1987) Inhibition of IgE-mediated histamine and peptide leukotriene release from human basophils and mast cells by forskolin. Biochem Pharmacol 36: 13–20
Hayes EC, Lombardo DL, Girard JY, Maycock AL, Rokach J, Rosenthal AS, Young RN, Egan RW, Zweerink HJ (1983) Measuring leukotrienes of slow reacting substance of anaphylaxis: development of a specific radioimmunoassay. J Immunol 131: 429–432
Schefler WC (1988) Statistics for Health Professionals. Addison-Wesley, Reading, MA
de Paulis A, Cirillo R, Ciccarelli A, Condorelli M, Marone G (1991) FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human FcεRI+ cells. J Immunol 146: 2374–2381
Genovese A, Spadaro G, Ciccarelli A, de Paulis A, Cirillo R, Marone G (1992) Modulation of mediator release from human FcεRI+ cells. In: Olivieri D, Barnes P, Hurd S, Folco G (eds) Asthma treatment. A multidisciplinary approach. Plenum, New York, pp 131–144
Marone G (1993) In vitro and in vivo modulation of human mast cells and basophils. In: Holgate ST, Austen KF, Lichtenstein LM, Kay AB (eds) Asthma: physiology and treatment: fourth international symposium. Academic Press, New York, pp 419–433
Casolaro V, Stellato C, de Crescenzo G, Triggiani M, Marone G: Human mast cells, basophils and their mediators. In: Olivieri D, Barnes P, Hurd S, Folco G (eds) Asthma treatment. A multidisciplinary approach. Plenum, New York, pp 63—79
Larsson EL (1980) Cyclosporin A and dexamethasone suppress T cell responses by selectively acting at distinct sites of the triggering process. J Immunol 124: 2828–2833 35. Gordon D, Nouri AME (1981) Comparison of the inhibition by glucocorticosteroids and cyclosporin A of mitogen-stimulated human lymphocyte proliferation. Clin Exp Immunol 44: 287-294 36. Reed JC, Abidi AH, Alpers JD, Hoover RG, Robb RJ, Nowell PC (1986) Effect of cyclosporin A and dexamethasone on interleukin 2 receptor gene expression. J Immunol 137: 150-154 37. Chiara MD, Sobrino F (1991) Modulation of the inhibition of respiratory burst in mouse macrophages by cyclosporin A: effect of in vivo treatment, glucocorticoids and the state of activation of cells. Immunology 72:133-137
Starzl TE, Klintmalm GB, Porter KA, Iwatsuki S, Schröter GPJ (1981) Liver transplantation with use of cyclosporin A and prednisone. N Engl J Med 305: 266–269
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marone, G., Stellato, C., Renda, A. et al. Anti-inflammatory effects of glucocorticoids and cyclosporin A on human basophils. Eur J Clin Pharmacol 45 (Suppl 1), S17–S20 (1993). https://doi.org/10.1007/BF01844198
Issue Date:
DOI: https://doi.org/10.1007/BF01844198